266 related articles for article (PubMed ID: 37450510)
1. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
3. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
4. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
5. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
[TBL] [Abstract][Full Text] [Related]
8. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
[TBL] [Abstract][Full Text] [Related]
9. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
[TBL] [Abstract][Full Text] [Related]
10. Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
Ramos-Duarte VA; Orlowski A; Jaquenod de Giusti C; Corigliano MG; Legarralde A; Mendoza-Morales LF; Atela A; Sánchez MA; Sander VA; Angel SO; Clemente M
Vaccine; 2024 May; 42(14):3355-3364. PubMed ID: 38631949
[TBL] [Abstract][Full Text] [Related]
11. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
12. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
[TBL] [Abstract][Full Text] [Related]
13. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
Alleva DG; Delpero AR; Scully MM; Murikipudi S; Ragupathy R; Greaves EK; Sathiyaseelan T; Haworth JR; Shah NJ; Rao V; Nagre S; Lancaster TM; Webb SS; Jasa AI; Ronca SE; Green FM; Elyard HA; Yee J; Klein J; Karnes L; Sollie F; Zion TC
Vaccine; 2021 Oct; 39(45):6601-6613. PubMed ID: 34642088
[TBL] [Abstract][Full Text] [Related]
14. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
15. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
16. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
Chiba S; Halfmann PJ; Iida S; Hirata Y; Sato Y; Kuroda M; Armbrust T; Spyra S; Suzuki T; Kawaoka Y
Vaccine; 2023 Sep; 41(41):6025-6035. PubMed ID: 37635002
[TBL] [Abstract][Full Text] [Related]
17. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
18. Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation.
Rodrigues-Jesus MJ; Teixeira de Pinho Favaro M; Venceslau-Carvalho AA; de Castro-Amarante MF; da Silva Almeida B; de Oliveira Silva M; Andreata-Santos R; Gomes Barbosa C; Brito SCM; Freitas-Junior LH; Boscardin SB; de Souza Ferreira LC
Nanomedicine; 2022 Sep; 45():102595. PubMed ID: 36031045
[TBL] [Abstract][Full Text] [Related]
19. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
[TBL] [Abstract][Full Text] [Related]
20. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
